Allarity Therapeutics (ALLR) AI Stock Analysis

• Market Cap: $15.60M
• Dividend Yield: N/A
• Average Volume (3M): 146.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.11
• Revenue Growth: N/A
• EPS Growth: 99.82%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 16,080,980
• 10 Day Avg. Volume: 114,973
• 30 Day Avg. Volume: 146,334
• PEG Ratio: <0.01
• Price to Book (P/B): 0.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.11
• Enterprise Value/Market Cap: <0.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $9.50
• Price Target Upside: 733.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.97
• Revenue Forecast (FY): $99.78M

• Rating: 40 Underperform
• Price Target: $0.84 ▼(-26.14% Downside)
• Action: Downgraded Date: 02/04/26
• Date: Action: Downgraded 02/04/26

The score is weighed down primarily by weak financial performance—no revenue, ongoing losses, and sustained negative free cash flow—despite modest leverage and currently positive equity. Technicals also detract due to a clear downtrend with negative momentum, while valuation is constrained by negative earnings and lack of dividend support.

Positive Factors

VA-funded Phase 2 trial enrollment

A VA-funded Phase 2 trial materially reduces near-term cash burden and accelerates clinical validation. Access to 11 VA sites improves patient recruitment and data quality, raising the structural probability of trial completion and future partner interest over the coming months.

DRP® companion diagnostic platform

The proprietary DRP companion diagnostic provides durable competitive differentiation by enabling targeted patient selection. This can improve trial hit rates, lower per-indication development costs, and strengthen licensing or partnership leverage across multiple oncology programs over the medium term.

Modest leverage and positive equity

Low absolute debt and recently positive equity provide a structural balance-sheet cushion relative to many early-stage peers. This reduces immediate insolvency risk and gives management flexibility to run trials or negotiate non-dilutive deals during the next 2-6 months.

Negative Factors

Persistent cash burn

Sustained negative operating and free cash flow shows the company is consuming capital faster than it generates it. This structural cash burn creates recurring funding needs, elevates dilution risk, and constrains R&D pacing and program expansion unless offset by external capital or milestone revenue.

No revenue and ongoing losses

Zero reported revenue and repeated operating losses indicate a pre-commercial profile dependent on clinical success. Absent near-term commercialization or sustainable licensing income, achieving profitability is unlikely within the medium term, limiting strategic optionality.

Reliance on dilutive equity financings

Frequent private placements and an equity purchase facility point to ongoing dependence on equity financing. This durable financing model raises shareholder dilution risk and can impair capital efficiency, potentially diverting management focus toward funding rather than program execution.

Allarity Therapeutics Business Overview & Revenue Model

Company Description

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Allarity Therapeutics, Inc. generates revenue primarily through strategic partnerships and licensing agreements with other pharmaceutical companies. These collaborations often involve upfront fees, milestone payments, and royalties on future sales of licensed products. The company's revenue model is heavily dependent on advancing its clinical pipeline and securing partnerships for drug development and commercialization. Additionally, Allarity may receive funding through grants and research collaborations aimed at supporting its innovative DRP technology and associated drug development efforts.

Allarity Therapeutics Financial Statement Overview

Summary

No revenue reported and ongoing sizable losses (TTM net income -$15.3M; EBIT -$17.0M) with persistent cash burn (TTM operating cash flow -$14.8M; free cash flow -$15.1M). Balance sheet leverage is modest and equity is currently positive, but the business remains highly funding-dependent.

Income Statement

The company reports zero revenue across all periods provided, while continuing to generate sizable operating losses. Profitability is consistently weak: TTM (Trailing-Twelve-Months) net income is -$15.3M and EBIT is -$17.0M, following a larger annual loss in 2024 (net income -$24.5M). A positive note is that losses narrowed from 2024 to TTM (Trailing-Twelve-Months), suggesting some cost containment, but the absence of revenue keeps the earnings profile high-risk and heavily dependent on future commercialization or funding.

Balance Sheet

Leverage appears modest in absolute terms (TTM total debt ~$1.39M), and equity is positive in the most recent periods (TTM equity ~$12.0M; 2024 equity ~$11.8M), which supports near-term balance sheet stability. However, the track record shows meaningful volatility—equity was negative in 2023 (-$2.8M), highlighting dilution/financing and accumulated-loss risk typical of early-stage biotech. Returns to shareholders are clearly unfavorable (TTM return on equity around -112%), reflecting ongoing losses despite the currently positive equity base.

Cash Flow

Cash generation remains a key weakness, with persistent cash burn: TTM (Trailing-Twelve-Months) operating cash flow is -$14.8M and free cash flow is -$15.1M, after even heavier cash outflows in 2024 (operating cash flow -$17.4M; free cash flow -$17.7M). While cash burn improved versus 2024, TTM free cash flow growth is still negative (-11.9%), and cash flows remain firmly negative overall. Free cash flow is roughly in line with reported losses (TTM free cash flow to net income ~1.02), indicating the losses are translating into real cash usage rather than being primarily non-cash.

Breakdown	TTM	Mar 2025	Dec 2023	Mar 2023	Mar 2022	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-15.09M	-24.23M	-11.28M	-17.30M	-25.77M	-6.01M
Net Income	-15.31M	-24.52M	-11.90M	-16.06M	-26.65M	-6.60M
Balance Sheet
Total Assets	20.80M	22.65M	11.86M	14.54M	49.63M	33.40M
Cash, Cash Equivalents and Short-Term Investments	16.89M	19.53M	166.00K	2.03M	19.91M	298.00K
Total Debt	1.39M	1.35M	1.30M	3.73M	1.09M	2.67M
Total Liabilities	8.79M	10.84M	14.61M	12.65M	30.85M	8.96M
Stockholders Equity	12.01M	11.81M	-2.75M	1.89M	18.78M	24.44M
Cash Flow
Free Cash Flow	-15.08M	-17.65M	-12.74M	-16.84M	-15.05M	-7.25M
Operating Cash Flow	-14.78M	-17.35M	-12.74M	-16.82M	-15.05M	-7.25M
Investing Cash Flow	-298.00K	-298.00K	0.00	791.00K	1.00M	-3.00K
Financing Cash Flow	15.12M	36.79M	10.99M	-1.31M	33.82M	6.03M

Allarity Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLR, the sentiment is Neutral. The current price of 1.14 is above the 20-day moving average (MA) of 0.91, above the 50-day MA of 1.04, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 49.40 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALLR.

Allarity Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LSTA	52 Neutral	$36.17M	-1.93	-71.45%	―	―	15.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRIS	45 Neutral	$15.66M	-0.31	―	―	13.56%	52.92%
ALLR	40 Underperform	$15.60M	-0.60	-122.61%	―	―	99.82%
LGVN	40 Underperform	$11.55M	-0.40	-119.92%	―	-22.41%	78.88%

Allarity Therapeutics Corporate Events

Allarity Therapeutics Secures Flexible Equity Financing Facility

On January 28, 2026, Allarity Therapeutics, Inc. entered into a Common Stock Purchase Agreement with Tumim Stone Capital LLC, giving the company the right, but not the obligation, to sell up to $6 million of newly issued common shares, or a lower amount if capped by exchange rules. The shares may be sold in tranches at discounts to specified volume-weighted average prices and are subject to limits on trade size, ownership thresholds for the investor, and an exchange cap that restricts issuance to 19.99% of pre-agreement outstanding shares unless shareholders later approve a waiver or the minimum price condition is met; Allarity paid a $45,000 commitment fee for the facility, which provides a flexible source of equity financing but also introduces potential dilution for existing shareholders.

The most recent analyst rating on (ALLR) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.

Allarity Therapeutics Completes Additional Private Equity Financing

On September 22, 2025, Allarity Therapeutics entered into a securities purchase agreement with an accredited investor for a private placement of 1,562,500 shares of common stock and/or pre-funded warrants, raising approximately $2.5 million in gross proceeds, and on December 23, 2025, the company completed an additional closing under that agreement. At this additional closing, Allarity sold a further 255,103 common shares at $0.98 per share, the minimum price permitted under Nasdaq rules, generating about $250,000 in gross proceeds that it plans to use for general corporate purposes and working capital, with the unregistered securities issued under a private placement exemption and subject to restrictive legends, highlighting the company’s continued reliance on exempt equity financings to support its operations.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.

Allarity Therapeutics Appoints Jeffrey Ervin as Full-Time CFO

On December 3, 2025, Allarity Therapeutics, Inc. transitioned Jeffrey S. Ervin from a part-time to a full-time Chief Financial Officer role under a new employment agreement. This agreement includes an annual base salary of $367,700, restricted stock units, and a performance bonus, reflecting the company’s commitment to strengthening its financial leadership.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.25 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.